{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:58:29Z","timestamp":1775483909858,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jmoldx.2023.01.009","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T21:12:43Z","timestamp":1675977163000},"page":"274-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Next-CLL, a New Next-Generation Sequencing\u2013Based Method for Assessment of IGHV Gene Mutational Status in Chronic Lymphoid\u00a0Leukemia"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-6863","authenticated-orcid":false,"given":"Estelle","family":"Bourbon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaddour","family":"Chabane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Mosnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Bouvard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Thonier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Ferrant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Poulain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Hayette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Sujobert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3408-2783","authenticated-orcid":false,"given":"Sarah","family":"Huet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2023.01.009_bib1","doi-asserted-by":"crossref","first-page":"15746","DOI":"10.1038\/ncomms15746","article-title":"Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia","volume":"8","author":"Minici","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib2","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3324\/haematol.2018.207399","article-title":"Another step forward in the 20-year history of IGHV mutations in chronic lymphocytic leukemia","volume":"104","author":"Del Giudice","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib4","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib5","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib6","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/asheducation-2017.1.338","article-title":"Optimizing frontline therapy of CLL based on clinical and biological factors","volume":"2017","author":"Fischer","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib11","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib13","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib14","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib15","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib16","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41375-022-01604-2","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL","volume":"36","author":"Agathangelidis","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib17","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/leu.2017.125","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations","volume":"31","author":"Rosenquist","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib18","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1038\/s41375-020-0923-9","article-title":"Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing","volume":"34","author":"Davi","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2404457","article-title":"ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia","volume":"21","author":"Ghia","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib20","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Kr\u00f6ber","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib21","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2004-11-4516","article-title":"Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL","volume":"106","author":"Austen","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib22","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/s41375-020-0716-1","article-title":"Impact of using leader primers for IGHV mutational status assessment in chronic lymphocytic leukemia","volume":"34","author":"Huet","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib23","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1080\/10428194.2021.1933476","article-title":"Reliable IGHV status assessment by next generation sequencing in routine practice for chronic lymphocytic leukemia","volume":"62","author":"Boulland","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jmoldx.2021.06.005","article-title":"Next-generation sequencing-based clonality assessment of Ig gene rearrangements: a multicenter validation study by EuroClonality-NGS","volume":"23","author":"van den Brand","year":"2021","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib25","series-title":"Immunoglobulin gene analysis: technical aspects. Immunoglobulin gene analysis in Chronic Lymphocytic Leukemia","first-page":"23","author":"Langerak","year":"2009"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib26","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"van Dongen JJM","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib27","doi-asserted-by":"crossref","first-page":"W503","DOI":"10.1093\/nar\/gkn316","article-title":"IMGT\/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis","volume":"36","author":"Brochet","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0161-5890(92)90100-C","article-title":"Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire","volume":"29","author":"Campbell","year":"1992","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib29","doi-asserted-by":"crossref","first-page":"e0185056","DOI":"10.1371\/journal.pone.0185056","article-title":"BBMerge\u2014accurate paired shotgun read merging via overlap","volume":"12","author":"Bushnell","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib30","doi-asserted-by":"crossref","first-page":"e0166126","DOI":"10.1371\/journal.pone.0166126","article-title":"Vidjil: a web platform for analysis of high-throughput repertoire sequencing","volume":"11","author":"Duez","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib31","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.4049\/jimmunol.1602050","article-title":"High-throughput immunogenetics for clinical and research applications in immunohematology: potential and challenges","volume":"198","author":"Langerak","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/leu.2016.307","article-title":"Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia","volume":"31","author":"Stamatopoulos","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3324\/haematol.2013.087593","article-title":"Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones","volume":"99","author":"Plevova","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.23396","article-title":"Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia","volume":"88","author":"Visco","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib35","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.leu.2402537","article-title":"Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course","volume":"16","author":"Stilgenbauer","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib36","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1182\/blood.V99.11.4087","article-title":"B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes","volume":"99","author":"Damle","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib37","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","article-title":"Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells","volume":"194","author":"Klein","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib38","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/sj.leu.2402731","article-title":"Do CLL B cells correspond to naive or memory B-lymphocytes? Evidence for an active Ig switch unrelated to phenotype expression and Ig mutational pattern in B-CLL cells","volume":"16","author":"Oppezzo","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib39","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1084\/jem.20120833","article-title":"Cellular origin and pathophysiology of chronic lymphocytic leukemia","volume":"209","author":"Seifert","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib40","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ng.2443","article-title":"Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia","volume":"44","author":"Kulis","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib41","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1080\/10428194.2022.2038375","article-title":"CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia","volume":"63","author":"Perkins","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib42","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.hoc.2021.03.002","article-title":"Potential relevance of B-cell maturation pathways in defining the cell(s) of origin for chronic lymphocytic leukemia","volume":"35","author":"Ng","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000491382","article-title":"Why is the immunoglobulin heavy chain gene mutation status a prognostic indicator in chronic lymphocytic leukemia?","volume":"140","author":"Rozovski","year":"2018","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jmoldx.2023.01.009_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.15018","article-title":"The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab","volume":"180","author":"Jain","year":"2018","journal-title":"Br J Haematol"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157823000259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157823000259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:17:43Z","timestamp":1761502663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157823000259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1525157823000259"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2023.01.009","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-CLL, a New Next-Generation Sequencing\u2013Based Method for Assessment of IGHV Gene Mutational Status in Chronic Lymphoid\u00a0Leukemia","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2023.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}